Showing results (211-220 of 335) with videos related to

Sort By:
Pageof 34
Communications Biology|March 24, 2021
Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosisRyan S Dhindsa, Johan Mattsson, Abhishek Nag, et al.
Annals of Internal Medicine|November 27, 2018
The Burden of Candidate Pathogenic Variants for Kidney and Genitourinary Disorders Emerging From Exome SequencingHila Milo Rasouly, Emily E Groopman, Reuben Heyman-Kantor, et al.
The Journal of Infectious Diseases|October 5, 2010
Determinants of protection among HIV‐exposed seronegative persons: an overviewMichael M Lederman, Galit Alter, Demetre C Daskalakis, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 27, 2009
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance doseAmarjit S Chaudhry, Thomas J Urban, Jatinder K Lamba, et al.
Nature Genetics|December 21, 2004
A single-nucleotide polymorphism tagging set for human drug metabolism and transportKourosh R Ahmadi, Mike E Weale, Zhengyu Y Xue, et al.
Plos Genetics|November 30, 2017
A case-control collapsing analysis identifies epilepsy genes implicated in trio sequencing studies focused on de novo mutationsXiaolin Zhu, Raghavendra Padmanabhan, Brett Copeland, et al.
American Journal of Human Genetics|September 4, 2012
Using ERDS to infer copy-number variants in high-coverage genomesMingfu Zhu, Anna C Need, Yujun Han, et al.
The Lancet. Neurology|April 18, 2014
Distinct neurological disorders with ATP1A3 mutationsErin L Heinzen, Alexis Arzimanoglou, Allison Brashear, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
Hepatology (Baltimore, Md.)|January 29, 2011
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRAlexander J Thompson, Rosanna Santoro, Valeria Piazzolla, et al.
Pageof 34